Patents Issued in June 10, 2014
-
Patent number: 8748092Abstract: The invention provides methods and compositions for rapid, sensitive, and highly specific nucleic acid-based (e.g., DNA based) detection of a BK virus in a sample. In general, the methods involve detecting a target nucleic acid having a target sequence of a conserved region of BK viral genomes. The invention also features compositions, including primers, probes, and kits, for use in the methods of the invention.Type: GrantFiled: January 12, 2011Date of Patent: June 10, 2014Assignee: Focus Diagnostics, Inc.Inventors: Fan Chen, Lilly I. Kong, Jules Chen, Mehrdad Jannatipour
-
Patent number: 8748093Abstract: A method of detecting a fungus belonging to genus Geosmithia, including identifying a fungus belonging to genus Geosmithia using a nucleic acid represented by the nucleotide sequence defined in the following (a) or (b): (a) a partial nucleotide sequence of ?-tubulin gene shown in any one of SEQ ID NOS: 1 to 3, or a complementary sequence thereof; (b) a nucleotide sequence including deletion, substitution, insertion or addition of one or several nucleotide(s) in the nucleotide sequence shown in any one of SEQ ID NOS: 1 to 3, or a complementary sequence thereof.Type: GrantFiled: November 11, 2009Date of Patent: June 10, 2014Assignee: Kao CorporationInventors: Kouichi Hosoya, Motokazu Nakayama, Hajime Tokuda, Takashi Yaguchi, Yusuke Hiro
-
Patent number: 8748094Abstract: This invention generally relates to particle-assisted nucleic acid sequencing. In some embodiments, sequencing may be performed in a microfluidic device, which can offer desirable properties, for example, minimal use of reagents, facile scale-up, and/or high throughput. In one embodiment, a target nucleic acid may be exposed to particles having nucleic acid probes. By determining the binding of the particles to the target nucleic acid, the sequence of the target nucleic acid (or at least a portion of the target nucleic acid) can be determined. The target nucleic acid may be encapsulated within a fluidic droplet with the particles having nucleic acid probes, in certain instances. In some cases, the sequence of the target nucleic acid may be determined, based on binding of the particles, using sequencing by hybridization (SBH) algorithms or other known techniques.Type: GrantFiled: December 18, 2009Date of Patent: June 10, 2014Assignee: President and Fellows of Harvard CollegeInventors: David A. Weitz, Adam R. Abate
-
Patent number: 8748095Abstract: The present invention provides a polymorphism detection probe that can identify a polymorphism in an EGFR gene easily and with high reliability and a polymorphism detection method using the probe. The probe of the present invention is a probe for detecting a polymorphism in an EGFR gene, including at least one of an oligonucleotide (P1) and an oligonucleotide (P2), wherein: (P1) is a 22- to 50-mer oligonucleotide composed of a base sequence complementary to a base sequence including 334th to 355th bases in SEQ ID NO: 1 and having a base complementary to the 334th base in its 3? end region; and (P2) is an oligonucleotide composed of a base sequence complementary to the oligonucleotide (P1).Type: GrantFiled: October 29, 2010Date of Patent: June 10, 2014Assignee: ARKRAY, Inc.Inventor: Moeko Ijuin
-
Patent number: 8748096Abstract: The present invention provides an isolated nucleic acid molecule containing a repeat region of an isolated spinocerebellar ataxia type 8 (SCA8) coding sequence, the coding sequence located within the long arm of chromosome 13, and the complement of the nucleic acid molecule. Diagnostic methods based on identification of this repeat region are also provided.Type: GrantFiled: August 20, 2012Date of Patent: June 10, 2014Assignee: Regents of the University of MinnesotaInventors: Laura P. W. Ranum, Michael D. Koob, Kellie A. Benzow, Melinda L. Moseley-Alldredge
-
Patent number: 8748097Abstract: The present invention provides systems for identifying genes and gene products associated with nitrogenous bisphosphonate treatment (NBP) treatment of calcium disorders. The invention also provides systems for identify and/or characterizing agents in treating calcium disorders. The invention further provides systems for diagnosing a calcium disorder and monitoring treatment of a subject.Type: GrantFiled: December 3, 2012Date of Patent: June 10, 2014Assignees: President and Fellows of Harvard College, Whitehead Institute for Biomedical ResearchInventors: Erin O'Shea, Timothy Peterson, Thijn Brummelkamp, David M. Sabatini
-
Patent number: 8748098Abstract: Described herein are compositions and methods for the diagnosis, prognosis, prevention and treatment of melanoma or melanoma associated symptoms. The compositions are microRNA molecules associated with melanoma, as well as various nucleic acid molecules relating thereto or derived therefrom.Type: GrantFiled: August 8, 2012Date of Patent: June 10, 2014Assignee: New York UniversityInventors: Eva Hernando, Miguel Segura, Douglas Hanniford, Silvia Menendez
-
Patent number: 8748099Abstract: The invention provides for a diagnostic test to monitor cancer-specific genetic abnormalities to diagnose cervical cell disorders and predict which patients might progress to cancer. Genetic abnormalities are detected by identification in chromosomal copy number of chromosome 3 and chromosome 5 using FISH analysis of probes targeted to 3q and/or 5p.Type: GrantFiled: November 1, 2013Date of Patent: June 10, 2014Assignee: NeoDiagnostix, Inc.Inventors: Gregory Anton Endress, Madhvi Upender, Elizabeth Light, Colyn Cain
-
Patent number: 8748100Abstract: Disclosed herein are methods and kits for selectively amplifying, detecting or quantifying a DNA fragment with a specific end sequence, especially generated following restriction enzyme digestion. This method can be used, for example, to detect a hypomethylated DNA fragment. This methods and kits are especially useful in detecting or quantifying a hypomethylated fetal DNA fragment in a maternal plasma sample containing a corresponding hypermethylated maternal DNA fragment.Type: GrantFiled: August 30, 2007Date of Patent: June 10, 2014Assignee: The Chinese University of Hong KongInventors: Yuk Ming Dennis Lo, Yu Kwan Tong, Wai Kwun Rossa Chiu, Chunming Ding
-
Patent number: 8748101Abstract: Methods, compositions, and devices are disclosed which use microRNA to detect, predict, treat, and monitor physiological conditions such as disease or injury. microRNA are isolated and their differential expression is measured to provide diagnostic information. This information may then be utilized for evaluation and/or treatment purposes.Type: GrantFiled: November 10, 2009Date of Patent: June 10, 2014Assignees: Battelle Memorial Institute, Institute for Systems Biology, The Ohio State University Research FoundationInventors: David Galas, Richard Evan Gelinas, Clay Braden Marsh, Melissa Garnet Piper, Kai Wang, Shile Zhang
-
Patent number: 8748102Abstract: Disclosed are methods for nucleic acid amplification wherein nucleic acid templates, beads, and amplification reaction solution are emulsified and the nucleic acid templates are amplified to provide clonal copies of the nucleic acid templates attached to the beads. Also disclosed are kits and apparatuses for performing the methods of the invention.Type: GrantFiled: February 23, 2011Date of Patent: June 10, 2014Assignee: 454 Life Sciences CorporationInventors: Jan Berka, Yi-Ju Chen, John H. Leamon, Steve Lefkowitz, Kenton L. Lohman, Vinod B. Makhijani, Jonathan M. Rothberg, Gary J. Sarkis, Maithreyan Srinivasan, Michael P. Weiner
-
Patent number: 8748103Abstract: There is a need for improved methods for determining the diagnosis and prognosis of patients with conditions, including autoimmune disease and cancer, especially lymphoid neoplasms, such as lymphomas and leukemias. Provided herein are methods for using DNA sequencing to identify personalized, or patient-specific biomarkers in patients with lymphoid neoplasms, autoimmune disease and other conditions. Identified biomarkers can be used to determine and/or monitor the disease state for a subject with an associated lymphoid disorder or autoimmune disease or other condition. In particular, the invention provides a sensitive method for monitoring lymphoid neoplasms that undergo clonal evolutions without the need to development alternative assays for the evolved or mutated clones serving as patient-specific biomarkers.Type: GrantFiled: May 4, 2011Date of Patent: June 10, 2014Assignee: Sequenta, Inc.Inventors: Malek Faham, Thomas Willis
-
Patent number: 8748104Abstract: The invention provides aptamers capable of binding to the skeletal Troponin I protein useful as diagnostics of skeletal muscle damage in which the skeletal Troponin I protein has been implicated.Type: GrantFiled: May 23, 2013Date of Patent: June 10, 2014Assignee: eNano Health LimitedInventors: Patrick Shau-park Leung, Yuk Yu Leon, Yun Chung Chow
-
Patent number: 8748105Abstract: The invention relates to the field of candidate drug testing and drug development. A method is provided for providing a compound composed of at least one molecule attached via at least two linkages to a molecular scaffold, the method comprising providing a scaffold comprising at least a first and a second reactive group; providing at least one molecule capable of reacting with the at least first and second reactive group; contacting the scaffold with at least one molecule to form at least two linkages between the scaffold and the at least one molecule in a coupling reaction, wherein the formation of a linkage accelerates the formation of a consecutive linkage, preferably wherein the coupling reaction is performed in solution, more preferably in an aqueous solution. Furthermore, a method is provided for selecting a candidate drug compound comprising providing a library of compounds according to the invention and determining the binding of a target molecule to the compounds.Type: GrantFiled: August 26, 2005Date of Patent: June 10, 2014Assignee: Pepscan Systems B.V.Inventors: Peter Timmerman, Joris Beld, Robbert Hans Meloen, Wouter Cornelis Puijk
-
Patent number: 8748106Abstract: This application is based, inter alia, on the discovery of a binding interaction between the Hn-33 hemagglutinin polypeptide of the type A Clostridium botulinum neurotoxin complex and synaptosomal proteins, including synaptotagmin II (Syt II). Methods of screening for compounds that modulate, e.g., increase or decrease, this interaction are provided. Also provided are compositions and methods for targeting compounds to neuronal and cancer cells by coupling the compounds to Hn-33 or biologically active Hn-33 variants.Type: GrantFiled: April 18, 2006Date of Patent: June 10, 2014Inventors: Bal Ram Singh, Yu Zhou
-
Patent number: 8748107Abstract: The present invention provides antibodies which bind to CXC chemokine receptor 4 (CXCR4) and which do not induce significant apoptosis of CXCR4 expressing cells. Also provided are inter alia immunoconjugates and compositions comprising such antibodies and methods and uses involving such antibodies, particularly in the medical and diagnostic fields.Type: GrantFiled: February 10, 2011Date of Patent: June 10, 2014Assignee: Affitech Research ASInventors: Anita Kavlie, Sergej Michailovic Kiprijanov
-
Patent number: 8748108Abstract: Disclosed are methods for classifying a patient with cancer as a candidate for therapy with a Bcl-2 family inhibitor comprising determining the level of at least one biomarker in a sample and comparing the biomarker level to a threshold level. Also described are methods for identifying classes of patients having a refractory cancer for second-line therapy comprising a Bcl-2 family inhibitor, where the method comprises determining the level of at least one biomarker in a sample and comparing the biomarker level to a threshold level.Type: GrantFiled: December 6, 2011Date of Patent: June 10, 2014Assignee: AbbVie Inc.Inventors: Evelyn M. McKeegan, Barry L. Dowell, Richard R. Lesniewski, Dimitrí Semizarov
-
Patent number: 8748109Abstract: This invention relates to methodology for detecting, assessing and/or diagnosing the presence of organ or tissue injury. More specifically, the present invention relates to methodology for detecting particular serum biomarkers that can be used in the detection, assessment and/or diagnosis of organ (e.g. liver) or tissue (e.g. skin) injury.Type: GrantFiled: July 5, 2010Date of Patent: June 10, 2014Assignee: The University of LiverpoolInventors: Daniel Antoine, Dominic Williams, Kevin Park
-
Patent number: 8748110Abstract: Methods of treating a subject having a cardiovascular disease, selecting a therapy for a subject having a cardiovascular disease, identifying a subject having a cardiovascular disease that will benefit or not benefit from exercise therapy, determining whether a subject having a cardiovascular disease should begin, continue, not begin, discontinue, or avoid exercise therapy, determining whether a subject having a cardiovascular disease should continue, discontinue, or avoid exercise therapy, reducing the risk of an adverse outcome (e.g., death) in a subject having a cardiovascular disease, and predicting the efficacy of exercise therapy in a subject having a cardiovascular disease. These methods include determining a level of soluble ST2 in a subject.Type: GrantFiled: July 18, 2012Date of Patent: June 10, 2014Assignee: Critical Care Diagnostics, Inc.Inventors: James V. Snider, Robert W. Gerwien
-
Patent number: 8748111Abstract: The invention provides a bio-sensing nanodevice comprising: a stabilized G-protein coupled receptor on a support, a real time receptor-ligand binding detection method, a test composition delivery system and a test composition recognition program. The G-protein coupled receptor can be stabilized using surfactant peptide. The nanodevice provides a greater surface area for better precision and sensitivity to odorant detection. The invention further provides a microfluidic chip containing a stabilized G-protein coupled receptor immobilized on a support, and arranged in at least two dimensional microarray system. The invention also provides a method of delivering odorant comprising the step of manipulating the bubbles in complex microfluidic networks wherein the bubbles travel in a microfluidic channel carrying a variety of gas samples to a precise location on a chip. The invention further provides method of fabricating hOR17-4 olfactory receptor.Type: GrantFiled: January 28, 2011Date of Patent: June 10, 2014Assignee: Massachusetts Institute of TechnologyInventors: Andreas Mershin, Brian Cook, Liselotte Kaiser, Johanna F. Bikker, Yoshikatsu Miura, Daisuke Niwa, Dai Ohnishi, Atsushi Tazuke, Shuguang Zhang
-
Patent number: 8748112Abstract: The present invention is based on the discovery that the Notch signaling pathway is associated with cancer. Accordingly, the invention provides methods and compositions for treating cancer. Also provided are methods of modulating the expression and/or activity of proteins in the Notch signaling pathway for use in diagnoses and treatment of cancer in a subject.Type: GrantFiled: February 17, 2012Date of Patent: June 10, 2014Assignee: Trojan Technologies, Ltd.Inventor: Spyros Stylianou
-
Patent number: 8748113Abstract: Provided herein are compositions, methods, and kits useful for detecting whether a subject has or is likely to develop a cancer and for monitoring, staging and examining a cancer patient. Also provide herein are methods for screening compounds.Type: GrantFiled: November 12, 2008Date of Patent: June 10, 2014Assignee: The Johns Hopkins UniversityInventors: William Matsui, Richard J. Jones, Carol A. Huff
-
Patent number: 8748114Abstract: It has been surprisingly found that ZAP-70 expression, both at the protein and mRNA levels, is indicative of clinical subgroups of CLL/SLL patients. In particular, high ZAP-70 expression is indicative of Ig-unmutated CLL/SLL. Methods are provided for discriminating between clinical subgroups of CLL/SLL, by determining whether subjects overexpress ZAP-70 mRNA or protein.Type: GrantFiled: June 7, 2011Date of Patent: June 10, 2014Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Louis M. Staudt, Andreas Rosenwald, Wyndham Wilson, Todd S. Barry, Adrian Wiestner
-
Patent number: 8748115Abstract: Methods of using PCSK9 antagonists More specifically, methods for measuring circulating PCSK9 levels in a biological sample by means of an immunoassay The immunoassay used can be a solid phase immunoassay, such as a dissociation-enhanced lanthanide fluorescence immunoassay utilizing an E07 capture antibody or coating and a G08 or H23 detecting antibody.Type: GrantFiled: December 2, 2009Date of Patent: June 10, 2014Assignee: Merck Sharp & Dohme Corp.Inventors: Yan Ni, Ayesha Sitlani, Shilpa Pandit, Dale Lewis, Xun Shen, Sharon Lobo, Timothy McCabe, Jon Condra, Rose Cubbon
-
Patent number: 8748116Abstract: This invention pertains to methods and compositions for the diagnosis and treatment of cardiovascular conditions. More specifically, the invention relates to isolated molecules that can be used to diagnose and/or treat cardiovascular conditions including cardiac hypertrophy, myocardial infarction, stroke, arteriosclerosis, and heart failure.Type: GrantFiled: March 7, 2013Date of Patent: June 10, 2014Assignee: The Brigham and Women's Hospital, Inc.Inventor: Richard T. Lee
-
Patent number: 8748117Abstract: Probe 1 for detection and quantification of nitric oxide, which comprises two subunits 21 and 22 of soluble guanylate cyclase 2 and cGMP-visualization probes 3 respectively connected with each subunit, wherein the cGMP-visualization probe generates signal upon recognizing guanosine 3?,5?-cyclic monophospate.Type: GrantFiled: May 9, 2011Date of Patent: June 10, 2014Assignee: Japan Science and Technology AgencyInventors: Yoshio Umezawa, Moritoshi Sato
-
Patent number: 8748118Abstract: The present invention is directed to the field of cancer diagnosis, specifically to the diagnosis of bladder cancer (BC) and prostate cancer (CaP). More specifically, the invention provides simple, non-invasive urinary tests characterized by high sensitivity and specificity, wherein urinary levels of heat shock proteins and anti-inflammatory cytokines are used as biomarkers.Type: GrantFiled: August 3, 2010Date of Patent: June 10, 2014Assignees: Yeda Research and Development Co. Ltd., Mor—Research Applications Ltd.Inventors: Irun R. Cohen, Meirav Pevsner-Fischer, David Margel, Jack Baniel, Ofer Yossepowitch
-
Patent number: 8748119Abstract: One aspect of the present disclosure encompasses methods for determining a protein kinase or phosphatase activity in a biological sample, comprising: contacting in a reaction mix a first test sample and a fluorescently-labeled peptide substrate capable of being modified by a protein phosphatase or a protein kinase, contacting the reaction mix with a TiO2 matrix, thereby partitioning fluorescently-labeled phosphorylated peptide from fluorescently-labeled dephosphorylated peptide; and determining the fluorescence of the fluorescently-labeled dephosphorylated peptide, thereby determining a protein kinase or phosphatase activity.Type: GrantFiled: December 6, 2012Date of Patent: June 10, 2014Assignee: Emory UniversityInventors: Jennifer L. Gooch, Brian R. Roberts, Jan Pohl
-
Patent number: 8748120Abstract: In one embodiment of the invention, there is provided a method of selecting a surface chemistry for culturing a given cell line, including the steps of: (i) providing a first substrate having a plasma polymerized surface with first and second regions, said first region having a first concentration of carboxylic acid groups on said plasma polymerized surface and said second region having a second concentration of carboxylic acid groups on said plasma polymerized surface, wherein said first and second concentrations are different; (ii) culturing cells from said cell line on said plasma polymerized surface in each said region; (iii) observing activity of said cultured cells in each said region, said activity selected from the group consisting of alkaline phosphatase activity of the cultured cells, cell growth of the cultured cells, attachment of the cultured cells, and cell spreading of the cultured cells; and iv) selecting, based on a particular observed activity, a secondary substrate for culturing said cellsType: GrantFiled: July 29, 2013Date of Patent: June 10, 2014Assignee: Corning IncorporatedInventors: Robert Short, Patricia Murray, Kristina Parry
-
Patent number: 8748121Abstract: The invention relates to biomarkers of oxidative stress and their use. Specifically, the invention relates to thiadiazabicyclo-4-oxo-2(E)-nonenal-Glutathione adduct as a biomarker of oxidative stress and its diagnostic use.Type: GrantFiled: October 23, 2007Date of Patent: June 10, 2014Assignee: The Trustees of the University of PennsylvaniaInventors: Ian Blair, Clementina Mesaros, Wenying Jian, Seon Hwa Lee, Tomoyuki Oe
-
Patent number: 8748122Abstract: The present invention relates to methods and systems for scanning, detecting, and monitoring microorganisms on solid or semi-solid media using intrinsic fluorescence (IF) measurements. The methods are further directed to detection, characterization and/or identification of microorganisms on a solid or semi-solid media using intrinsic fluorescence (IF) measurements that are characteristic of said microorganisms.Type: GrantFiled: December 15, 2009Date of Patent: June 10, 2014Assignee: bio Mérieux, Inc.Inventors: Jones Hyman, John Walsh, Thurman Thorpe
-
Patent number: 8748123Abstract: The presently disclosed subject matter concerns a microbial biopolymer comprising fucose in its composition. This biopolymer consists of a polysaccharide comprising fucose, which represents at least 10% of its composition. This fucose-containing polysaccharide also contains non-sugar components, namely, acyl group substituents. This disclosed subject matter also concerns the process for the production of the biopolymer, which is obtained cultivation of the bacterium Enterobacter A47 (DSM 23139), using glycerol or glycerol-rich mixtures as carbon sources. The fucose-containing biopolymer of the presently disclosed subject matter may be used in several industrial applications (e.g. pharmaceutical, cosmetics and agro-food industries) and in the treatment of industrial wastes (e.g. oil and metal recovery).Type: GrantFiled: December 15, 2010Date of Patent: June 10, 2014Assignee: 73100-Setenta e Tres Mil e Cem, Lda.Inventors: Maria D'Ascensão Carvalho Fernandes De Miranda Reis, Rui Manuel Freitas Oliveira, Maria Filomena Andrade De Freitas, Vítor Manuel Delgado Alves
-
Patent number: 8748124Abstract: Disclosed are novel microbial compositions and biodegradation processes to treat marine animal or marine animal by-products to produce solid, liquid and lipid fractions that contain useful compounds.Type: GrantFiled: December 21, 2010Date of Patent: June 10, 2014Assignee: Agrinos ASInventors: Jamie López-Cervantes, Dalia Isabel Sánchez-Machado, Karl Reiner Fick Rochin
-
Patent number: 8748125Abstract: The present invention relates to non-steroidal ligands for use in nuclear receptor-based inducible gene expression system, and a method to modulate exogenous gene expression in which an ecdysone receptor complex comprising: a DNA binding domain; a ligand binding domain; a transactivation domain; and a ligand is contacted with a DNA construct comprising: the exogenous gene and a response element; wherein the exogenous gene is under the control of the response element and binding of the DNA binding domain to the response element in the presence of the ligand results in activation or suppression of the gene.Type: GrantFiled: August 13, 2007Date of Patent: June 10, 2014Assignee: Intrexon CorporationInventors: Robert Eugene Hormann, Colin M. Tice, Orestes Chortyk, Howard Smith, Thomas Meteyer
-
Patent number: 8748126Abstract: Induction of tolerance to antigens by mucosal, preferably oral, delivery of the antigen in combination with an immunomodulating compound producing micro-organism is disclosed. More specifically, Foxp3+ and/or IL-10 and/or TGF-? producing regulatory T-cells are induced which are capable of suppressing undesired immune responses toward an antigen. The antigen is preferably delivered orally in combination with an immunosuppressing cytokine secreting micro-organism.Type: GrantFiled: November 29, 2006Date of Patent: June 10, 2014Assignee: Actogenix N.V.Inventors: Pieter Rottiers, Veerle Snoeck
-
Patent number: 8748127Abstract: The invention relates to a truncated L1 protein of the Human Papillomavirus Type 6, a virus-like particle consisting of the protein, a vaccine comprising said virus-like particle, and the use of the vaccine in the prevention of condyloma acuminatum or HPV infections.Type: GrantFiled: May 29, 2008Date of Patent: June 10, 2014Assignees: Xiamen University, Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.Inventors: Shaowei Li, Huirong Pan, Bo Liu, Jun Zhang, Ji Miao, Ningshao Xia
-
Patent number: 8748128Abstract: Four novel transporter genes were successfully cloned by screening novel transporter genes based on the human OATP transporter gene sequence. These transporters are useful in the development of drugs by taking advantage of the activity of transporting biological substances and various drugs. It was also found that these transporter genes have single nucleotide polymorphisms (SNP). Gene diagnosis based on the polymorphisms (such as SNP) in these transporter genes enables one to judge, for example, the efficacy of a drug therapy.Type: GrantFiled: April 13, 2010Date of Patent: June 10, 2014Assignees: Chugai Seiyaku Kabushiki KaishaInventors: Jun-Ichi Nezu, Asuka Ose, Akira Tsuji
-
Patent number: 8748129Abstract: This invention concerns a method for the targeted integration of at least three copies of a gene of interest in the genome of a Yarrowia strain including the steps of: (a) cultivating a Yarrowia strain, said strain including a deletion among at least three genes, the phenotype associated with each of these deletions corresponding to an auxotrophy or to a dominant character for this strain; (b) transforming said Yarrowia strain thus obtained with at least three recombinant vectors that include selection markers allowing, for this strain, the complementation of auxotrophy and, potentially, of the dominant character resulting from each of these deletions; and (c) selecting, on a minimum medium, the yeasts having integrated said at least three recombinant vectors.Type: GrantFiled: February 5, 2009Date of Patent: June 10, 2014Assignee: Institut National de la Recherche AgronomiqueInventors: Jean-Marc Nicaud, Franck Fudalej, Cécile Neuveglise, Jean-Marie Beckerich
-
Patent number: 8748130Abstract: The present invention is directed towards compositions comprising Ii-Key/HPV hybrid peptides. The hybrid peptides of the present invention are effective in the generation of CD4+ helper T cell immune responses directed towards the specific HPV epitopes encoded in the hybrid peptide. The inclusion of the Ii-key peptide in the hybrid causes the peptide to have greater immunogenicity as compared to control peptide. The inclusion of Ii-Key/HPV hybrid in a peptide vaccine formulation composing both HPV hybrid and HPV CTL epitope peptide (administered concurrently or sequentially) leads to a greater CTL activity against HPV CTL epitopes. The hybrid peptides of the present invention may be useful, for example, for the immunization of subjects against HPV.Type: GrantFiled: September 1, 2009Date of Patent: June 10, 2014Assignee: Antigen Express, Inc.Inventors: Minzhen Xu, Eric von Hofe
-
Patent number: 8748131Abstract: Composition containing a chimeric neuregulin polypeptides and method of making such polypeptides are disclosed. The chimeric neuregulin comprises a first moiety of at least 10 amino acids, wherein the first moiety is derived from a first polypeptide; and a second moiety of at least 5 amino acids, wherein the second moiety is derived from a second polypeptide; wherein the first polypeptide is a neuregulin and the chimeric neuregulin exhibits an enhanced binding affinity to integrin, Erb 3, or Erb 4 comparing to that of the first neuregulin.Type: GrantFiled: September 26, 2012Date of Patent: June 10, 2014Assignee: Morehouse School of MedicineInventor: Byron D. Ford
-
Patent number: 8748132Abstract: A process for preparing an inclusion body-forming protein is provided. A nucleic acid fragment having a nucleotide sequence coding for a modified alkaline phosphatase signal peptide (modified APSP) where leucine at the 13th position in the amino acid sequence shown in SEQ ID NO: 1 is substituted with proline and/or alanine at the 21st position is substituted with the other amino acid, downstream of which nucleotide sequence is bound a nucleotide sequence of a gene of a protein of interest is also provided.Type: GrantFiled: October 21, 2009Date of Patent: June 10, 2014Assignees: The Chemo-Sero-Therapeutic Research Institute, Teijin Pharma LimitedInventors: Hiroshi Nakatake, Akihiro Meta, Kiyotaka Suenaga, Masaki Hirashima, Hiroaki Maeda
-
Patent number: 8748133Abstract: Provided are compositions, kits, and methods for the identification of Listeria. In certain aspects and embodiments, the compositions, kits, and methods may provide improvements in relation to specificity, sensitivity, and speed of detection.Type: GrantFiled: December 29, 2009Date of Patent: June 10, 2014Assignee: Gen-Probe IncorporatedInventors: Michael R. Reshatoff, Kristin W. Livezey, James J. Hogan
-
Patent number: 8748134Abstract: Described herein are techniques for assembling a polynucleotide encoding a transcription activator-like effector nucleases (TALEN). The techniques ligate and digest necessary modules for a TALEN assembly in one reactor or system. Methods and Kits for generating a TALEN are also described.Type: GrantFiled: September 26, 2013Date of Patent: June 10, 2014Assignee: SIDANSAI Biotechnology Co., LtdInventors: Jinlong Zhao, Zhao Wu
-
Patent number: 8748135Abstract: ?-1,4-galactosyltransferase (CgtD) polypeptides, nucleic acids that encode the polypeptides, including a polypeptide from Campylobacter jejuni strain LIO87 have been isolated and characterized. A method of producing a galactosylated saccharide comprising contacting an acceptor saccharide containing a terminal galactose, a donor substrate comprising a galactose moiety and one of the CgtD polypeptides is described.Type: GrantFiled: November 28, 2012Date of Patent: June 10, 2014Assignee: National Research Council of CanadaInventors: Michel Gilbert, Warren Wakarchuk, Scott Houliston
-
Patent number: 8748136Abstract: The present invention relates to a method for the production of methionine or its derivatives by culturing a microorganism in an appropriate culture medium comprising a source of carbon and a source of sulphur. The microorganism and/or the culture medium and/or the process parameters were modified in a way that the accumulation of the by-product N-acyl-methionine (NAM) is reduced. The isolation of methionine or its derivatives from the fermentation medium is also claimed.Type: GrantFiled: February 12, 2009Date of Patent: June 10, 2014Assignee: Metabolic ExplorerInventors: Rainer Figge, Philippe Soucaille, Gwénaëlle Bestel-Corre
-
Patent number: 8748137Abstract: It is an object of the present invention to provide a method for efficiently producing a polylactate via microbial fermentation with the use of a sugar as a starting material.Type: GrantFiled: October 27, 2009Date of Patent: June 10, 2014Assignee: Toyota Jidosha Kabushiki KaishaInventors: Shusei Obata, Hiromi Kambe, Masakazu Ito, Takashi Shimamura, Katsunori Kohda, Seiichi Taguchi
-
Patent number: 8748138Abstract: A method or process for producing polyhydroxyalkanoates (PHAs) in biomass. The process entails feeding an organic carbon containing substrate to biomass enriched in PHA accumulating bacteria. Particularly the process entails intermittently supplying the substrate to the biomass at least three separate times over a selected period. The object of the process is to produce PHA having a relatively high molecular weight, at least 400,000 g/mole. By controlling the frequency at which the substrate is supplied to the biomass and by feeding a sufficient amount of the substrate to the biomass, the method or process produces the PHA having the relatively high molecular weight.Type: GrantFiled: December 10, 2010Date of Patent: June 10, 2014Assignee: Veolia Water Solutions & Technologies SupportInventors: Alan Gideon Werker, Simon Olof Harald Bengtsson, Carl Anton Börje Karlsson
-
Patent number: 8748139Abstract: DNA constructs and genetically engineered microbial strains constructed using these DNA constructs, which produce a nuclease enzyme with specificity for DNA and/or RNA, are provided. These strains secrete nuclease into the periplasm or growth medium in an amount effective to enhance productivity and/or recovery of polymer, and are particularly suited for use in high cell density fermentation processes. These constructs are useful for modifying microbial strains to improve production and recovery processes for polymers such as intracellular proteins, such as enzymes, growth factors, and cytokines; for producing polyhydroxyalkanoates; and for producing extracellular polysaccharides, such as xanthan gum, alginates, gellan gum, zooglan, hyaluronic acid and microbial cellulose.Type: GrantFiled: June 27, 2003Date of Patent: June 10, 2014Assignee: Metabolix, Inc.Inventors: Gjalt W. Huisman, Laura Z. Luo, Oliver P. Peoples
-
Patent number: 8748140Abstract: The present disclosure provides compositions and methods related to the fermentation of xylose. Host cells having recombinant polynucleotides encoding one or more of aldose reductases, xylitol dehydrogenases, and xylulokinase are provided herein. Host cells having reduced expression of PHO13 are also provided herein. Also provided herein are uses of host cells provided herein, and methods relating to the use of xylose-containing materials.Type: GrantFiled: October 19, 2012Date of Patent: June 10, 2014Assignee: The Board of Trustees of the University of IllinoisInventors: Yong-Su Jin, Soo Rin Kim, Suk-Jin Ha
-
Patent number: 8748141Abstract: The present invention relates to methods for producing high levels of alcohol during fermentation of plant material, and to the high alcohol beer produced. The method can include fractionating the plant material. The present invention also relates to methods for producing high protein distiller's dried grain from fermentation of plant material, and to the high protein distiller's dried grain produced. The method can include drying a co-product by ring drying, flash drying, or fluid bed drying. The present invention further relates to reduced stack emissions from drying distillation products from the production of ethanol.Type: GrantFiled: March 25, 2013Date of Patent: June 10, 2014Assignee: Poet Research, Inc.Inventors: Stephen M. Lewis, Shon Erron Van Hulzen